相关实验视频

Updated: Jun 5, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

在患有血液性恶性瘤的患者接受CAR T细胞治疗后,患者报告的结果

Xin Shelley Wang¹, Samer A Srour¹

¹University of Texas M.D. Anderson Cancer Center, Houston, TX.

Hematology. American Society of Hematology. Education Program

|December 7, 2024

概括

患者报告的结果 (PROs) 对于管理仿真抗原受体 (CAR) T细胞治疗毒性至关重要. 将PRO纳入护理指南可以个性化治疗并改善患者的治疗结果.

科学领域:

在瘤学瘤学.
血液学血液学血液学
以患者为中心的护理

背景情况:

化学抗原受体 (CAR) T细胞疗法显著改善了血液性恶性瘤的存活率.
卡尔T细胞疗法具有独特的毒性和高症状负担,需要以患者为中心的评估.
患者报告的结果 (PROs) 可以增强个性化干预和优化资源使用.

研究的目的:

审查目前在CAR T细胞治疗中使用PRO的现状.
识别阻碍PRO整合到常规患者护理中的障碍.
讨论PRO实施的实际方法和未来方向.

主要方法:

在CAR T细胞治疗中对PROs的文献综述.
分析影响PRO在临床实践中的可行性和实用性的因素.
讨论基于证据的PRO整合策略.

主要成果:

在急性CAR-T细胞治疗期间,尤其是神经毒性时,PRO评估的可行性尚未得到充分确立.
临床试验中的当前PRO工具往往无法捕获用于常规监测的临床上有意义的不良事件.
关于使用PRO来监测CAR T细胞治疗幸存者的长期影响的数据有限.

结论:

在CAR T细胞治疗护理中整合PRO的障碍必须克服.
在标准护理指南中需要基于证据的PRO.
成功实施需要实践方法和未来的研究.

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.